Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSynairgen Share News (SNG)

Share Price Information for Synairgen (SNG)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 6.20
Bid: 5.52
Ask: 7.00
Change: 0.08 (1.31%)
Spread: 1.48 (26.812%)
Open: 6.20
High: 6.20
Low: 6.20
Prev. Close: 6.12
SNG Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

finnCap Interim Profit More Than Doubles; Chair To Step Down

Wed, 18th Nov 2020 13:59

(Alliance News) - finnCap Group PLC on Wednesday said profit in the first half of its financial year more than doubled amid increased equity fundraising from clients.

Shares in finnCap were up 12% at 21.80 pence in London in afternoon trading.

The London-based stockbroker reported a GBP3.6 million pretax profit for the six months ended September 30, more than twice the GBP1.4 million profit reported in the prior year.

This came as revenue jumped 44% to GBP20.5 million from GBP14.2 million.

finnCap explained: "Against our initial expectations, activity in our markets in H1 has been strong, with increased equity fundraisings to support our clients' financial needs and investment in strong business cases. We have also benefited from on-going long-term investment in building leading expertise in the healthcare, biotech and tech sectors where there has been significant corporate activity.

"As a result, revenue generation in H1 has proven to be stronger than we expected and, with cost actions outlined above, we have therefore delivered materially higher profits and cashflow than in H1 last year."

The firm raised more than GBP300 million across 15 equity fundraisings for listed clients, plus 2 initial public offerings. It also advised on 4 completed takeovers and public company advisory roles worth GBP212 million total.

finnCap said its financial third quarter has started well with the completion of the Fonix Mobile PLC IPO, which raised GBP45 million, as well as a GBP87 million placing and open offer for Synairgen PLC. It is expecting "a good result" for financial 20201, which ends March 31, "well ahead of the prior year". finnCap also expects its disposal of a 70% holding in PrimaryBid Ltd, for approximately GBP700,000, to complete in early 2021.

Jon Moulton, finnCap's chief executive officer, it to retire at the end of December, succeeded by Robert Lister. Lister, who joins finnCap January 1, "spent 25 years in investment banking first with Barclays de Zoete Wedd where he started as a graduate in 1983 and rose to become head of European Equities in 1998 and then at Dresdner Kleinwort Benson where he was global head of Equities."

Howard Leigh will step down from the board, becoming senior partner of newly integrated Corporate Finance (UK) Ltd.

Chief Executive Sam Smith said: "Our strategy of developing a full suite of products for growth companies - which, we believe, differentiates us from our peers - is delivering incremental revenue. Having completed the integration of Cavendish, we are now moving into a key phase of our strategy - carefully seeking bolt on acquisitions in adjacent sectors which align with our culture and further our vision of building a more broadly-based group, focused on servicing growing companies' needs.

"The uncertain operating environment means we must remain cautious, however, Q3 has started well, with the completion of the IPO of Fonix Mobile and a further large fund raising for Synairgen and our pipeline of deals remains good."

The company declared a 0.5 pence per share interim dividend, having ceased dividend payments in financial 2020.

Additionally, finnCap noted its chief financial officer, Richard Snow, bought 95,364 shares at 22.65 pence each, worth GBP21,600, on Wednesday. Snow now is interested in 328,697 shares, a 0.2% stake.

By Anna Farley; annafarley@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
20 Jan 2021 21:16

IN BRIEF: Synairgen Recruits Covid-19 Patients Into Phase II Trial

IN BRIEF: Synairgen Recruits Covid-19 Patients Into Phase II Trial

Read more
13 Jan 2021 10:24

Synairgen Doses First Patient In Covid-19 Treatment Trial

Synairgen Doses First Patient In Covid-19 Treatment Trial

Read more
11 Jan 2021 20:54

COVID SCIENCE-COVID-19 patients still have symptoms 6 months later; interferon may be helpful treatment after all

By Nancy LapidJan 11 (Reuters) - The following is a roundup of some of the latest scientific studies on the novel coronavirus and efforts to find treatments and vaccines for COVID-19, the illness caused by the virus.Half a year later, COVID-19 pat...

Read more
18 Dec 2020 12:08

LONDON MARKET MIDDAY: FTSE 100 Rises As Crunch Brexit Talks Dent Pound

LONDON MARKET MIDDAY: FTSE 100 Rises As Crunch Brexit Talks Dent Pound

Read more
18 Dec 2020 11:06

Synairgen Gets Fast Track Designation From US FDA For Covid-19 Vaccine

Synairgen Gets Fast Track Designation From US FDA For Covid-19 Vaccine

Read more
18 Dec 2020 10:29

Synairgen makes solid progress with Covid-19 treatment

(Sharecast News) - Respiratory drug development company Synairgen updated the market on its phase 3 trial design evaluating SNG001 as a treatment for patients with Covid-19 on Friday, as well as positive progress on its regulatory path.

Read more
13 Nov 2020 14:28

Synairgen surges on positive results for Covid-19 treatment

(Sharecast News) - Synairgen shares surged on Friday after data from trials of its inhaled Covid-19 treatment, SNG001, published in The Lancet Respiratory Medicine, showed positive results in hospitalised patients.

Read more
13 Nov 2020 10:24

Synairgen Drug Helps Recovery In Hospitalised Covid-19 Patients

Synairgen Drug Helps Recovery In Hospitalised Covid-19 Patients

Read more
2 Nov 2020 20:03

UK TRADING UPDATE SUMMARY: Sensyne App Used In Oxford Covid Study

UK TRADING UPDATE SUMMARY: Sensyne App Used In Oxford Covid Study

Read more
15 Oct 2020 11:39

Synairgen Raises GBP80 Million In Placing, To Launch Open Offer

Synairgen Raises GBP80 Million In Placing, To Launch Open Offer

Read more
14 Oct 2020 18:02

IN BRIEF: Synairgen Looks To Raise GBP80 Million For SNG001 Trial

IN BRIEF: Synairgen Looks To Raise GBP80 Million For SNG001 Trial

Read more
29 Sep 2020 12:14

Synairgen Progresses Covid-19 Treatment As Expenses Increase

Synairgen Progresses Covid-19 Treatment As Expenses Increase

Read more
9 Sep 2020 16:04

IN BRIEF: Synairgen Makes Inhaled Interferon Beta Patent Application

IN BRIEF: Synairgen Makes Inhaled Interferon Beta Patent Application

Read more
9 Sep 2020 12:23

Synairgen files for another patent on 'SNG001'

(Sharecast News) - Respiratory drug development company Synairgen updated the market on its intellectual property for the wholly-owned inhaled interferon beta asset 'SNG001' on Wednesday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.